In the interim, however, with PD-L1 expression still the only validated biomarker for predicting response of NSCLC to anti-PD-1/PD-L1 IMs, an optimal approach to improved tumour sampling may be guided by the intended therapeutic target. The gene discussed is CD274; the disease is neoplasm.